Positive hepatitis B surface antigen tests due to recent vaccination: a persistent problem

Rysgaard, Carolyn D.; Morris, Cory S.; Drees, Denny; Bebber, Tami; Davis, Scott R.; Kulhavy, Jeff; Krasowski, Matthew D.
January 2012
BMC Clinical Pathology;2012, Vol. 12 Issue 1, p15
Academic Journal
Background: Hepatitis B virus (HBV) is a common cause of viral hepatitis with significant health complications including cirrhosis and hepatocellular carcinoma. Assays for hepatitis B surface antigen (HBsAg) are the most frequently used tests to detect HBV infection. Vaccination for HBV can produce transiently detectable levels of HBsAg in patients. However, the time course and duration of this effect is unclear. The objective of this retrospective study was to clarify the frequency and duration of transient HBsAg positivity following vaccination against HBV. Methods: The electronic medical record at an academic tertiary care medical center was searched to identify all orders for HBsAg within a 17 month time period. Detailed chart review was performed to identify all patients who were administered HBV vaccine within 180 days prior to HBsAg testing and also to ascertain likely cause of weakly positive (grayzone) results. Results: During the 17 month study period, 11,719 HBsAg tests were ordered on 9,930 patients. There were 34 tests performed on 34 patients who received HBV vaccine 14 days or less prior to HBsAg testing. Of these 34 patients, 11 had grayzone results for HBsAg that could be attributed to recent vaccination. Ten of the 11 patients were renal dialysis patients who were receiving HBsAg testing as part of routine and ongoing monitoring. Beyond 14 days, there were no reactive or grayzone HBsAg tests that could be attributed to recent HBV vaccination. HBsAg results reached a peak COI two to three days following vaccination before decaying. Further analysis of all the grayzone results within the 17 month study period (43 results out of 11,719 tests) revealed that only 4 of 43 were the result of true HBV infection as verified by confirmatory testing. Conclusions: Our study confirms that transient HBsAg positivity can occur in patients following HBV vaccination. The results suggest this positivity is unlikely to persist beyond 14 days post-vaccination. Our study also demonstrates that weakly positive HBsAg results often do not reflect actual HBV infection, underscoring the importance of confirmatory testing. This study also emphasizes that vaccination-induced HBsAg positives occur most commonly in hemodialysis patients.


Related Articles

  • Hepatocellular Carcinoma.  // Clinical Infectious Diseases;5/1/2006, Vol. 42 Issue 9, following pe78 

    The article reports that the risk of development of cirrhosis and of hepatocellular carcinoma increases in patients with chronic hepatitis B virus (HBV) infection. The risk for the development of hepatocellular carcinoma begins to increase when HBV DNA level starts increasing alarmingly. It also...

  • Role of Hepatitis B Virus Precore/Core Promoter Mutations and Serum Viral Load on Noncirrhotic Hepatocellular Carcinoma: A Case-Control Study. Chun-Jen Liu; Bing-Fang Chen; Pei-Jer Chen; Ming-Yang Lai; Wen-Ling Huang; Jia-Horng Kao; Ding-Shinn Chen // Journal of Infectious Diseases;9/1/2006, Vol. 194 Issue 5, p594 

    Background. Apart from the presence of liver cirrhosis, hepatitis B virus (HBV) factors have also been shown to play a role in the development of hepatocellular carcinoma (HCC). Studying HBV-related noncirrhotic HCC may help clarify the effect of viral factors. Methods. In a hospital-based, age-...

  • α-Fetoprotein and Its Concanavalin A Affinity in Acute Exacerbation of Chronic Hepatitis B. Sun-Sang Wang; Govindarajan, Sugantha; Shou-Dong Lee; Ashcavai, Mary // American Journal of Gastroenterology;Jan1989, Vol. 84 Issue 1, p46 

    Serum samples from 20 patients with acute exacerbation of chronic hepatitis due to hepatitis B virus and 20 patients with hepatocellular carcinoma arising from B viral cirrhosis with elevated levels of α-fetoprotein (AFP) were analyzed by affinity column chromatography for concanavalin A...

  • Hepatitis B Vaccination and Hepatocellular Carcinoma Rates in Boys and Girls. Mei-Hwei Chang; Wen-Yi Shau; Chien-Jen Chen; Tzee-Chung Wu; Man-Shan Kong; Der-Cherng Liang; Hsu-Mei Hsu; Huey-Ling Chen; Hong-Yuan Hsu; Ding-Shinn Chen // JAMA: Journal of the American Medical Association;12/20/2000, Vol. 284 Issue 23, p3040 

    Presents a study to evaluate the association between a hepatitis B virus (HBV) vaccination program with incidence of childhood hepatocellular carcinoma (HCC) by sex. Design and setting; Participants; Main outcome measure; Results; Conclusion that boys may benefit more from HBV vaccination than...

  • HEPATITIS B: NEWS FROM THE RESEARCH WORLD. Piramanayagam, Paramasivan; Choudhuri, Gourdas; Singh, Shivaram Prasad // Hepatitis B Annual;2009, Vol. 6, p141 

    Despite the development of an effective vaccine, hepatitis B is still the leading cause of chronic viral hepatitis across the world, especially in developing countries, with over 400 million people across the world estimated to be harboring the infection. This section of the journal highlights a...

  • An MLP Classifier for Prediction of HBV-Induced Liver Cirrhosis Using Routinely Available Clinical Parameters. Yuan Cao; Zhi-De Hu; Xiao-Fei Liu; An-Mei Deng; Cheng-Jin Hu // Disease Markers;2013, Vol. 35 Issue 6, p653 

    Background. Liver cirrhosis (LC) is the final stage of most of chronic liver diseases and is almost caused by chronic hepatitis B (CHB) in China. Liver biopsy is the reference method for the evaluation of liver cirrhosis. However, it is an invasive procedure with inherent risk. The aim of this...

  • Prevention of hepatitis B virus infection: from the past to the future. Orlando, R.; Foggia, M.; Maraolo, A.; Mascolo, S.; Palmiero, G.; Tambaro, O.; Tosone, G. // European Journal of Clinical Microbiology & Infectious Diseases;Jun2015, Vol. 34 Issue 6, p1059 

    About 3-5 % of the world's population is chronically infected by hepatitis B virus (HBV) and is at risk of developing liver cirrhosis or hepatocellular carcinoma. The risk of dying prematurely because of chronic HBV infection is higher in younger people. The current strategies to prevent HBV...

  • Correction: Distinct Distribution Pattern of Hepatitis B Virus Genotype C and D in Liver Tissue and Serum of Dual Genotype Infected Liver Cirrhosis and Hepatocellular Carcinoma Patients.  // PLoS ONE;Oct2014, Vol. 9 Issue 10, p1 

    No abstract available.

  • The Increasing Burden of Imported Chronic Hepatitis B -- United States, 1974-2008. Mitchell, Tarissa; Armstrong, Gregory L.; Hu, Dale J.; Wasley, Annemarie; Painter, John A. // PLoS ONE;2011, Vol. 6 Issue 12, p1 

    Background: Without intervention, up to 25% of individuals chronically infected with hepatitis B virus (HBV) die of late complications, including cirrhosis and liver cancer. The United States, which in 1991 implemented a strategy to eliminate HBV transmission through universal immunization, is a...

  • Therapeutic vaccines in treating chronic hepatitis B: the end of the beginning or the beginning of the end? Michel, Marie-Louise; Bourgine, Maryline; Fontaine, Hélène; Pol, Stanislas // Medical Microbiology & Immunology;Feb2015, Vol. 204 Issue 1, p121 

    The antiviral treatment of chronic hepatitis B virus (HBV) infection has greatly improved over the last 20 years since it has allowed a disappearance of cirrhosis decompensation and a significant reduction of the incidence of hepatocellular carcinoma. However, a complete HBV cure has not been...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics